Treating Treatment-resistant Depression with Esketamine Nasal Spray When All Therapeutic Options Have Been Exhausted: Clinical Experience from a Spanish Cohort of Expanded Use
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Treatment Resistant Depression (TRD) is commonly defined as the lack of response to two or more antidepressants with different mechanisms of action. Up to 30% of patients diagnosed with major depressive disorder might be considered to present TRD. The objective of this study was to assess the effectiveness and tolerability of esketamine in patients diagnosed with TRD, who were referred to our program after exhausting all available treatments. A secondary objective consisted in researching the relationship between response and previous use of electroconvulsive therapy. Methods: A prospective, observational study was carried out in patients enrolled in the expanded use of esketamine in our center. They received esketamine prior to its marketing authorisation, for therapeutic purposes. Sixteen subjects were analyzed. Effectiveness was assessed with the Montgomery-Asberg depression rating scale (MADRS). Patients were followed up to 4 months after the administration. Results: Esketamine showed a rapid, robust effect in improving depressive symptoms, with no specific correlation between outcome and any demographic or clinical traits evaluated. No differences were found between patients that previously received Electroconvulsive Therapy, and those that didn’t. 10 out of 16 patients responded (＞ 50% change in baseline MADRS scores), but only five achieved remission (＜ 12 points in the global MADRS score). We provide some recommendations, based on clinical experience, to improve tolerability and adherence, and to manage adverse effects. Conclusion: Results suggest that esketamine is a safe, effective and rapid-acting option for TRD. More studies are needed to properly assess predictors of response outcome.
Abstract
Objective: Treatment Resistant Depression (TRD) is commonly defined as the lack of response to two or more antidepressants with different mechanisms of action. Up to 30% of patients diagnosed with major depressive disorder might be considered to present TRD. The objective of this study was to assess the effectiveness and tolerability of esketamine in patients diagnosed with TRD, who were referred to our program after exhausting all available treatments. A secondary objective consisted in researching the relationship between response and previous use of electroconvulsive therapy. Methods: A prospective, observational study was carried out in patients enrolled in the expanded use of esketamine in our center. They received esketamine prior to its marketing authorisation, for therapeutic purposes. Sixteen subjects were analyzed. Effectiveness was assessed with the Montgomery-Asberg depression rating scale (MADRS). Patients were followed up to 4 months after the administration. Results: Esketamine showed a rapid, robust effect in improving depressive symptoms, with no specific correlation between outcome and any demographic or clinical traits evaluated. No differences were found between patients that previously received Electroconvulsive Therapy, and those that didn’t. 10 out of 16 patients responded (＞ 50% change in baseline MADRS scores), but only five achieved remission (＜ 12 points in the global MADRS score). We provide some recommendations, based on clinical experience, to improve tolerability and adherence, and to manage adverse effects. Conclusion: Results suggest that esketamine is a safe, effective and rapid-acting option for TRD. More studies are needed to properly assess predictors of response outcome.
참고문헌 (34)
- Samalin L, "Esketamine nasal spray in patients with treatment-resistant depression : The real-world experience in the French cohort early-access programme", Int J Psychiatry Clin Pract, 26, pp.352~362 (2022)
- Bulut Çakmak B, "Anxiety, depression, and anger in functional gastrointestinal disorders : A Cross-sectional observational study", Psychiatry Res, 268, pp.368~372 (2018)
- Holt RI, "Diabetes and depression", Curr Diab Rep, 14, pp.491~ (2014)
- COVID-19 Mental Disorders Collaborators, "Global prevalence and burden of depressive and anxiety disorders in 204countries and territories in 2020 due to the COVID-19pandemic", Lancet, 398, pp.1700~1712 (2021)
- Vieta E, "Epidemiology and costs of depressive disorder in Spain : The EPICO study", Eur Neuropsychopharmacol, 50, pp.93~103 (2021)
- Bachmann S, "Epidemiology of suicide and the psychiatric perspective", Int J Environ Res Public Health, 15, pp.1425~ (2018)
- Al-Harbi KS, "Treatment-resistant depression : Therapeutic trends, challenges, and future directions", Patient Prefer Adherence, 6, pp.369~388 (2012)
- Zhdanava M, "The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States", J Clin Psychiatry, 82, pp.20~ (2021)
- Sforzini L, "A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials", Mol Psychiatry, 27, pp.1286~1299 (2022)
- Voineskos D, "Management of treatment-resistant depression : Challenges and strategies", Neuropsychiatr Dis Treat, 16, pp.221~234 (2020)
- Molero P, "Antidepressant efficacy and tolerability of ketamine and esketamine : A critical review", CNS Drugs, 32, pp.411~420 (2018)
- Lima TM, "Use of ketamine and esketamine for depression : An overview of systematic reviews with meta-analyses", Eur J Clin Pharmacol, 78, pp.311~338 (2022)
- McIntyre RS, "Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression : An international expert opinion on the available evidence and implementation", Am J Psychiatry, 178, pp.383~399 (2021)
- Fedgchin M, "Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression : Results of a randomized, double-blind, activecontrolled study(TRANSFORM-1)", Int J Neuropsychopharmacol, 22, pp.616~630 (2019)
- Daly EJ, "Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression : A randomized clinical trial", JAMA Psychiatry, 76, pp.893~903 (2019)
- Popova V, "Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression : A randomized double-blind ac-tive-controlled study", Am J Psychiatry, 176, pp.428~438 (2019)
- Lobo A, "Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales", Med Clin(Barc), 118, pp.493~499 (2002)
- Montgomery SA, "A new depression scale designed to be sensitive to change", Br J Psychiatry, 134, pp.382~389 (1979)
- Bobes J, "Validation of the Spanish version of the Liebowitz social anxiety scale, social anxiety and distress scale and Sheehan disability inventory for the evaluation of social phobia", Med Clin(Barc), 112, pp.530~538 (1999)
- Vieta E, "Bipolar and unipolar depressions", pp.104~ (2019), Editorial Médica Panamericana
- Fekadu A, "A multidimensional tool to quantify treatment resistance in depression : The Maudsley staging method", J Clin Psychiatry, 70, pp.177~184 (2009)
- "Clinical practice guideline on the management of adult depression" (2014)[URL]
- Papakostas GI, "Efficacy of esketamine augmentation in major depressive disorder : A meta-analysis", J Clin Psychiatry, 81, pp.19~ (2020)
- Bukh JD, "The effect of prolonged duration of untreated depression on antidepressant treatment outcome", J Affect Disord, 145, pp.42~48 (2013)
- Angst J, "Longterm depression versus episodic major depression : Results from the prospective Zurich study of a community sample", J Affect Disord, 115, pp.112~121 (2009)
- Otte C, "Major depressive disorder", Nat Rev Dis Primers, 2, pp.16065~ (2016)
- Anand A, "Ketamine versus ECT for nonpsychotic treatment-resistant major depression", N Engl J Med, 388, pp.2315~2325 (2023)
- Correia-Melo FS, "Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression : A randomized, double-blind, non-inferiority study", J Affect Disord, 264, pp.527~534 (2020)
- Swainson J, "Esketamine for treatment resistant depression", Expert Rev Neurother, 19, pp.899~911 (2019)
- Veraart JKE, "Pharmacodynamic interactions between ketamine and psychiatric medications used in the treatment of depression : A systematic review", Int J Neuropsychopharmacol, 24, pp.808~831 (2021)
- Mathai DS, "The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder : A systematic review", J Affect Disord, 264, pp.123~129 (2020)
- Chen G, "Relationship between dissociation and antidepressant effects of esketamine nasal spray in patients with treatment-resistant depression", Int J Neuropsychopharmacol, 25, pp.269~279 (2022)
- Mathai DS, "Toward synergies of ketamine and psychotherapy", Front Psychol, 13, pp.868103~ (2022)
- Jesus-Nunes AP, "Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression", Hum Psychopharmacol, 37, pp.e2836~ (2022)